CARsgen Therapeutics

company

About

CARsgen is a leading immunotherapy company focused on the development of new chimeric antigen receptor

  • 501 - 1000

Details

Last Funding Type
Series B
Last Funding Money Raised
$30M
Industries
Health Diagnostics,Medical,Therapeutics
Founded date
Nov 1, 2014
Number Of Employee
501 - 1000
Operating Status
Active

CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$276M
CARsgen Therapeutics has raised a total of $276M in funding over 2 rounds. Their latest funding was raised on Nov 2, 2020 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 2, 2020 Series C $186M 1 Detail
Mar 2, 2018 Series C $60M 1 Detail
Jan 25, 2016 Series B $30M 2 Jolly Innovation Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
3
CARsgen Therapeutics is funded by 3 investors. Lilly Asia Ventures and Jolly Innovation Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Series C
Jolly Innovation Ventures Series C
JIC Genesis Fountain Healthcare Ventures Series B